ANAPIX medical

What ANAPIX medical does

ANAPIX medical is a French medical technology company founded in 2016 in Meyreuil (Bouches-du-Rhône) that develops AI-powered real-time skin imaging software for the early detection and screening of skin cancers, particularly melanoma. The company's flagship product, SkinApp, captures, analyses, and archives both dermoscopic and non-dermoscopic photographs of skin lesions alongside associated consultation records. SkinApp is offered in two variants: SkinApp Cabinet (also referred to as SkinApp Office) for individual dermatology practices, and SkinApp Réseau (SkinApp Network) for interprofessional coordination across healthcare networks and CPTS (Communautés Professionnelles Territoriales de Santé). The company was co-founded by a former CNRS research director specialising in medical imaging in oncology, and holds ISO 13485:2016 certification (the reference standard for medical device quality management) with HDS-certified health data hosting.

ANAPIX operates a dual commercial model. On the professional side, it sells software subscriptions (with a free one-month trial for dermatologists) to individual practitioners, CPTS, and health establishments. On the enterprise side, it sells on-site skin cancer screening campaigns to corporate employers covering populations from 30 to several thousand employees, deployable across single or multiple sites including DOM and abroad; campaigns are offered as one-time engagements or as multi-year subscriptions and combine on-site photography, dermatologist teleconsultations, and follow-up recommendations. Between June 2022 and December 2024 the enterprise business completed 130+ campaigns across 66 companies, screening 6,829 individuals and capturing 164,988 photographs (including 108 urgent cases, or 1.6% of those screened).

The company's customer base spans major French and multinational enterprises across pharmaceuticals (Sanofi), aerospace and defence (Naval Group, Thales, Airbus), automotive (Valeo, Plastic Omnium, Iveco, Bosch/Rexroth), energy management (Schneider Electric, Grid Solutions), rail (Alstom), retail (Leclerc), beverages (Pernod Ricard), media (TF1), medical technology (bioMérieux), insurance (Uniprevoyance), and real estate (Actis). Distribution is direct-to-customer via a professional website, dedicated contact channels per segment, LinkedIn, industry events (most recently VivaTech 2025, where the company unveiled a pharmacy-deployable skin cancer screening tool), and earned media in outlets including La Tribune, Le Figaro, and the Anatomie IA podcast. The company has received multiple regional innovation awards between 2016 and 2023 and is supported by institutional backers including CNRS, ANR, Eurobiomed, Université Aix-Marseille, Région Sud, and the European Union.

Name

ANAPIX medical

Legal name

SAS ANAPIX medical

Website

https://anapix-medical.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

ANAPIX medical is a French health technology company founded in 2016 that provides AI-powered real-time skin imaging software (SkinApp) to dermatologists, healthcare networks, and enterprises for early skin cancer detection and on-site workplace screening campaigns.

Ownership category

akta.pro rank

Product category

Dermatology Imaging Software

NAICS

Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

General & Medical Dermatology (HLAKACAA)

Keywords

• Dermatology imaging software
• AI skin cancer detection
• Melanoma screening platform
• Occupational health screening
• Medical device software

Headquarters

HQ city

Meyreuil

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. SkinApp Software Subscriptions: SkinApp is offered as a software service to dermatologists, healthcare professionals, CPTS, and health establishments, likely on a subscription or per-seat basis. The company offers a free one-month trial for dermatologists, suggesting a subscription model.
2. Enterprise Corporate Screening Campaigns: ANAPIX medical conducts on-site skin cancer screening campaigns at enterprise client sites, with populations ranging from 30 to thousands. Services are offered as one-time campaigns or recurring subscriptions, with dermatologists providing consultations and follow-up recommendations.
3. Professional Services: The company provides professional services including on-site dermatological consultations, teleconsultations, and clinical coordination for enterprise health programmes.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

ANAPIX medical develops and sells SkinApp, an AI-powered real-time skin imaging platform that enables dermatologists, healthcare networks and enterprises to capture, archive and analyze dermoscopic and non-dermoscopic photographs of skin lesions for the early detection and screening of melanoma and other skin cancers. The company also runs on-site enterprise skin cancer screening campaigns at client workplaces, delivered as one-off or recurring programmes integrating photography sessions, dermatologist teleconsultations and follow-up recommendations.

Product overview

ANAPIX medical offers SkinApp, an AI-powered real-time skin imaging platform designed for dermatologists, healthcare professionals, and enterprises. The core SkinApp product comes in two variants: SkinApp Cabinet (also referred to as SkinApp Office) for individual dermatology practices, and SkinApp Réseau (SkinApp Network) as an interprofessional coordination tool for healthcare networks and CPTS organizations. The company also developed a pharmacy-deployable skin cancer screening tool for broader preventive care deployment. All products focus on early detection and screening of skin cancers, particularly melanoma, using dermoscopic imaging and AI-assisted analysis.

Differentiator

Problem solved

Functional benefit

Brands

• SkinApp: A service for health professionals supporting skin cancer detection and screening, available as SkinApp Cabinet for individual dermatologists and SkinApp Réseau for interprofessional use.
• SkinShot

Products and services

• SkinApp AI-powered real-time skin imaging software that enables dermatologists and healthcare professionals to capture, securely archive and analyze dermoscopic and non-dermoscopic photographs of skin lesions for the detection and screening of skin cancers, with associated consultation data management. Sold as a subscription to dermatologists, CPTS networks and health establishments in France.
• SkinApp Cabinet (SkinApp Office) Variant of SkinApp adapted for individual dermatology practices, offering easy and rapid photo archiving with quality imaging capability, secure hosting that does not consume local computer memory, and AI-assisted diagnostic support for solo practitioners.
• SkinApp Réseau (SkinApp Network) Interprofessional variant of SkinApp that enables coordination across multiple healthcare professionals and CPTS (Communautés Professionnelles Territoriales de Santé) organizations, optimising interprofessional coordination for skin cancer screening and patient referral.
• Pharmacy-Deployable Skin Cancer Screening Tool Pharmacy-deployable AI-powered skin cancer screening solution that enables accessible early skin cancer detection outside of traditional clinical or hospital settings, targeted at pharmacist-led preventive screening workflows.
• Enterprise Skin Cancer Screening Campaigns (SkinApp Entreprises) On-site corporate skin cancer prevention and early-detection service for enterprises, combining photography sessions, AI-assisted image capture, dermatologist teleconsultations and follow-up recommendations. Offered as one-time campaigns or subscription arrangements to corporate HR and occupational health departments, deployable to populations from 30 to several thousand across single or multiple sites including DOM and abroad.

Quantifiable outcome

• 6,829 people screened, 164,988 photos taken, 603 consultations recommended, including 108 urgent cases (1.6%) across 130 campaigns at 66 companies (June 2022 – December 2024)
• +2 more outcomes

Named customers17 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Naval GroupcoreStrategic or Co-development PartnerNaval Group collaborated with ANAPIX medical to conduct on-site enterprise skin cancer screening campaigns for its employees. The partnership produced a week-long screening campaign that led Naval Group to plan expansion to additional sites and equip its occupational health services (SPST) for periodic screenings. Naval Group and ANAPIX jointly won the DUO category of the Trophées Bossons Futé 2023.
• Université Aix-MarseilleminorOthersUniversité Aix-Marseille is listed among ANAPIX medical's institutional supporters, suggesting collaboration in research or academic contexts.
• CNRScoreOthersANAPIX medical was co-founded by a former CNRS research director specialising in medical imaging in oncology. The company emerged from CNRS research and maintains a close relationship with the institution, which is listed as a key supporter.
• ANR (Agence Nationale de la Recherche)minorOthersANR is listed among ANAPIX medical's institutional supporters, indicating funding or research collaboration.
• EurobiomedminorOthersEurobiomed, a health tech cluster, is listed as an institutional supporter of ANAPIX medical.
• Incubateur ImpulseminorOthersIncubateur Impulse is listed among ANAPIX medical's supporters, suggesting the company was incubated through this programme.
• P-FactoryminorOthersP-Factory is listed as an institutional supporter of ANAPIX medical.
• Université de StrasbourgminorOthersUniversité de Strasbourg is listed among ANAPIX medical's institutional supporters.
• Institut de Biologie de ParisminorOthersInstitut de Biologie de Paris is listed among ANAPIX medical's institutional supporters.
• Institut de Logiciels de Strasbourg (LIS Lab)minorOthersInstitut de Logiciels de Strasbourg (LIS Lab) is listed among ANAPIX medical's institutional supporters.
• SATT (Société d'Accélération du Transfert de Technologies)minorOthersSATT is listed among ANAPIX medical's institutional supporters, indicating technology transfer collaboration.
• AKTANTISminorOthersAKTANTIS is listed among ANAPIX medical's institutional supporters.
• Région SudminorOthersRégion Sud is listed among ANAPIX medical's institutional supporters and granted the 'Smart Région' prize in 2016.
• Pépinière du Pays d'AixminorOthersThe Pépinière du Pays d'Aix business incubator is listed as an institutional supporter of ANAPIX medical.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Skin Analytics: UK-based AI dermatology company offering DERM, an AI-powered skin cancer screening platform used in NHS pathways. Directly comparable to ANAPIX medical's SkinApp as a regulated AI skin imaging tool for melanoma and skin cancer detection in clinical and population screening settings.
• SkinVision: Amsterdam-based health technology company offering a smartphone-based AI skin cancer detection app and services for insurers, pharmacies, and enterprises. Directly comparable to ANAPIX medical's combination of AI dermatology imaging and pharmacy/enterprise deployment channels.
• FotoFinder Systems: German manufacturer of AI-powered dermoscopic imaging systems (FotoFinder bodystudio ATBM) used by dermatologists for skin cancer screening and mole mapping. Directly comparable to ANAPIX medical's clinical dermoscopic imaging and AI analysis capabilities for dermatology practices.
• MetaOptima Technology: Canadian developer of DermEngine, an AI dermatology imaging and teledermatology platform used by clinicians worldwide. Directly comparable to ANAPIX medical's SkinApp Cabinet and Réseau offerings for individual dermatologists and interprofessional networks.
• Miiskin: Denmark-based digital health platform offering AI-assisted skin tracking, mole mapping, and remote dermatology consultations for consumers and clinicians. Directly comparable to ANAPIX medical's AI skin imaging and teleconsultation capabilities in the B2B2C and consumer dermatology space.

Broad incumbents

• DermAssist (Google Health): Google Health's AI dermatology assistant tool providing AI-powered skin condition analysis via smartphone. A broad incumbent in AI dermatology that competes in the same category as ANAPIX medical's AI skin imaging tools but operates at vastly greater scale and reach.
• Canfield Scientific: US-based provider of dermatology imaging systems (VECTRA, IntelliStudio) and software used by dermatologists, plastic surgeons, and research institutions. Comparable to ANAPIX medical as a broad incumbent in clinical skin imaging hardware and software, though not AI-first.

Emerging players

• DermaSensor: US-based medical device company developing a handheld, FDA-cleared spectroscopic tool for primary care skin cancer detection. An emerging player in point-of-care dermatology AI/sensor screening, partially comparable to ANAPIX medical's efforts to bring screening beyond dermatologists.
• MoleScope: Canadian developer of a smartphone-attached dermatoscope and AI-assisted mole mapping app (DermSensor by MetaOptima's related efforts). An emerging player in mobile dermoscopy and AI skin imaging comparable to ANAPIX medical's smartphone-accessible skin cancer screening tools.

Others

• Heine Optotechnik: German manufacturer of medical instruments including professional dermatoscopes used by dermatologists worldwide. An adjacent equipment supplier whose dermatoscope hardware is complementary to ANAPIX medical's software-based skin imaging platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/anapix-medical
• Xx.com/anapixmedical
• Facebookfacebook.com/ANAPIXmedical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ANAPIX medical